Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osaka-Based Sakai Chemical Industrial Expands Contract Pharmaceutical Production

This article was originally published in PharmAsia News

Executive Summary

Osaka-based drug maker Sakai Chemical Industrial will boost its Nagano, Osaka factory's capacity and operation rates with plans to expand its contract drug production business. Currently contracted by four pharmaceutical companies, Sakai produces 10 therapeutic and 25 over-the-counter drugs, with 1 million solid preparations and 100,000 liquid formulations per month. Sakai plans to increase the capacity to 2 million solids and 500,000 liquids and increase to 10 contract companies. The company also plans to be manufacture sprays, oral solutions and health foods. The company expects the income from the contract production business will increase to ¥1 billion from several hundred thousand yen. (Click here for more - Japanese language

You may also be interested in...



QUOTED. 3 December. Jessica Schubel.

A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.

Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing

Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.

Trump’s Last-Minute Push for Faster COVID-19 Vaccine Could Jeopardize Uptake

White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel